Philip Needleman

from Wikipedia, the free encyclopedia

Philip Needleman (born February 10, 1939 in Brooklyn ) is an American pharmacologist .

Life

Needleman graduated from the Philadelphia College of Pharmacy and Science with a bachelor's degree in 1960 and a master's degree in 1962. In 1964, he received his doctorate in pharmacology from the University of Maryland (School of Medicine). From 1965 he was at Washington University in St. Louis , where he was assistant professor in 1967 and professor in 1976. He stayed there until 1989 and was head of the Department of Pharmacology. In 1989 he became Senior Vice President of Monsanto and in 1993 President of Searle Research and Development. From 2000 to 2003 he was chief scientist and vice president of research and development for Pharmacia Corporation in Kalamazoo . From 2003 he was Associate Dean of the Washington University School of Medicine and on its Board of Trustees.

He dealt with the control of cardiovascular and kidney functions. He discovered the atrial natriuretic peptide (atrial natriuretic factor, a hormone with which the heart communicates with the kidney), the first peptides with angiotensin antagonist function and the mechanism of organic nitrate tolerance. He also dealt with the role of prostaglandins in arthritis and predicted (according to his not undisputed own account) Cox-2 , which was discovered around 1990 by three other groups (made public in 1992). At Monsanto / Searle he developed the Cox-2 inhibitor Celebrex , which was approved by the FDA in 1998. He also discovered the first thromboxane synthase inhibitor.

In 2005 he received the NAS Award for the Industrial Application of Science for elucidating the metabolism of arachidonic acid and its role in diseases and the production of prostacyclin and thromboxane . In 1974 he received the John J. Abel Award and in 1977, 1978, 1980 and 1987 the Wellcome Creesy Award in clinical pharmacology, and in 2001 the IRI Medal . He is a member of the National Academy of Sciences (1987) and the American Academy of Arts and Sciences (2015). From 1968 to 1973 he was an investigator for the American Heart Association, whose Research Achievement Award he received. In 1980 he received the Cochems Thrombosis Research Prize.

Fonts

  • P. Needleman, PC Isaakson: The discovery and function of Cox-2, J. Rheumatol. Suppl., Vol. 49, July 1997, pp. 6-8.

Web links

Individual evidence

  1. ↑ Dates of birth according to American Men and Women of Science , Thomson Gale 2004
  2. ↑ Searle merged with Monsanto in 1985
  3. ↑ 2000 resulted from the merger of Pharmacia and Upjohn with the Searle group of Monsanto. In 2003 Pharmacia went to Pfizer (the name "Searle" was given up).
  4. ↑ Tom Nesi, Poison Pills: The Untold Story of the Vioxx Drug Scandal, 2008, pp. 75ff
  5. ↑ Needleman's account was included in the article Superaspirin by Jerome Groopman, The New Yorker , June 15, 1998. pdf
personal data
SURNAME Needleman, Philip
BRIEF DESCRIPTION American pharmacologist
DATE OF BIRTH February 10, 1939
PLACE OF BIRTH Brooklyn